Processa Pharmaceuticals, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Processa Pharmaceuticals, Inc. (PCSA) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2023-11-13
- Processa Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-06-30 was $0.00.
- Processa Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-03-31 was $0.00.
- Processa Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00.
- Processa Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2023-08-10 | $0.00 derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | $0.00 derived: sum of 3 quarters · filed 2023-05-15 | $0.00 derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2022-08-11 | $0.00 derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2022-05-12 | $0.00 derived: sum of 3 quarters · filed 2022-05-12 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $0.00 10-K · filed 2022-03-30 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |